Kailera Therapeutics, Inc. 4

Chief Corporate Affairs Officer Kathleen Tregoning received a stock option award for 175,000 shares of Kailera Therapeutics, Inc. common stock at a $23.30 exercise price.

On July 6, 2026, Chief Corporate Affairs Officer Kathleen Tregoning of Kailera Therapeutics, Inc. received a stock option grant for 175,000 shares of common stock at an exercise price of $23.30 per share, with no shares vested at grant and all 175,000 underlying shares reported as beneficially owned following the award. The option has a ten-year term expiring July 6, 2036 and is structured to vest as to 25% of the underlying shares on June 29, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter, contingent on her continued service. This is a routine equity compensation award rather than an open-market purchase or sale, and the total notional value of the grant, based on the exercise price, is approximately $4.08 million, signaling a meaningful long-term incentive alignment with shareholders.

Filing Facts

CIK

2096997

Ticker

KLRA

Form

4

Source Type

fda

Accession

0001193125-26-298558

Alert Tier

6